PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy
Authors
Rolfes, VerenaIdel, Christian
Pries, Ralph
Plotze-Martin, Kirstin
Habermann, Jens
Gemoll, Timo
Bohnet, Sabine
Latz, Eicke
Ribbat-Idel, Julika
Franklin, Bernardo S.
Wollenberg, Barbara
UMass Chan Affiliations
Department of Medicine, Division of Infectious Diseases and ImmunologyDocument Type
Journal ArticlePublication Date
2018-06-08Keywords
atezolizumabbiomarkers for PD1-PD-L1 checkpoint therapy
head and neck cancer
tumor-educated platelets
Cancer Biology
Immunoprophylaxis and Therapy
Neoplasms
Therapeutics
Metadata
Show full item recordAbstract
Cancer immunotherapy has been revolutionised by drugs that enhance the ability of the immune system to detect and fight tumors. Immune checkpoint therapies that target the programmed death-1 receptor (PD-1), or its ligand (PD-L1) have shown unprecedented rates of durable clinical responses in patients with various cancer types. However, there is still a large fraction of patients that do not respond to checkpoint inhibitors, and the challenge remains to find cellular and molecular cues that could predict which patients would benefit from these therapies. Using a series of qualitative and quantitative methods we show here that PBMCs and platelets from smokers and patients with head and neck squamous cell carcinoma (HNSCC) or lung cancer express and up-regulate PD-L1 independently of tumor stage. Furthermore, treatment with Atezolizumab, a fully humanised monoclonal antibody against PD-L1, in 4 patients with lung cancer caused a decrease in PD-L1 expression in platelets, which was restored over 20 days. Altogether, our findings reveal the expression of the main therapeutic target in current checkpoint therapies in human platelets and highlight their potential as biomarkers to predict successful therapeutic outcomes.Source
Oncotarget. 2018 Jun 8;9(44):27460-27470. doi: 10.18632/oncotarget.25446. eCollection 2018 Jun 8. Link to article on publisher's site
DOI
10.18632/oncotarget.25446Permanent Link to this Item
http://hdl.handle.net/20.500.14038/40694PubMed ID
29937998Related Resources
Rights
Copyright : © 2018 Rolfes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Distribution License
http://creativecommons.org/licenses/by/3.0/ae974a485f413a2113503eed53cd6c53
10.18632/oncotarget.25446
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright : © 2018 Rolfes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.